These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31792707)

  • 21. Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: A systematic review and meta-analysis study.
    Waranugraha Y; Lin LY; Tsai CT
    Trends Cardiovasc Med; 2024 May; 34(4):225-233. PubMed ID: 36775218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis.
    Bai Y; Guo SD; Deng H; Shantsila A; Fauchier L; Ma CS; Lip GYH
    Age Ageing; 2018 Jan; 47(1):9-17. PubMed ID: 28985259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yan BP; Yu CM
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):23-35. PubMed ID: 23224686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis.
    Wang X; Fang L; Liu B; Zheng Y; Zeng J
    Heart Fail Rev; 2020 Nov; 25(6):973-983. PubMed ID: 31713086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
    Santarpia G; De Rosa S; Polimeni A; Giampà S; Micieli M; Curcio A; Indolfi C
    PLoS One; 2015; 10(5):e0126512. PubMed ID: 25974377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of the efficacy and safety of non-vitamin K antagonist oral anticoagulants with warfarin in Latin American patients with atrial fibrillation.
    Su Z; Zhang H; He W; Ma J; Zeng J; Jiang X
    Medicine (Baltimore); 2020 May; 99(18):e19542. PubMed ID: 32358343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis.
    Casula M; Fortuni F; Fabris F; Leonardi S; Gnecchi M; Sanzo A; Greco A; Rordorf R
    J Cardiovasc Med (Hagerstown); 2020 Aug; 21(8):570-576. PubMed ID: 32628422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
    Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
    Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients (≥80 years of age) with atrial fibrillation: systematic review and meta-analysis.
    Kang F; Su L; Fan S; Lv L; Luo B
    Intern Med J; 2023 Sep; 53(9):1524-1532. PubMed ID: 37178051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
    Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
    Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta-analysis.
    Dai Q; Deng X; Zhou L; Zhang L; Xiao X; Liao Y
    Clin Cardiol; 2020 Jul; 43(7):676-683. PubMed ID: 32557677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation.
    Creta A; Hunter RJ; Earley MJ; Finlay M; Dhinoja M; Sporton S; Chow A; Mohiddin SA; Boveda S; Adragao P; Jebberi Z; Matos D; Schilling RJ; Lambiase PD; Providência R
    J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2626-2631. PubMed ID: 32639666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.